Advanced Cell Technology, Cytomedix and Mesoblast to Provide Corporate and Clinical Updates at Regen Med Investor Day

  Advanced Cell Technology, Cytomedix and Mesoblast to Provide Corporate and
                  Clinical Updates at Regen Med Investor Day

- Alliance for Regenerative Medicine Announces Final Disease Session
Panelists; 16 leading regenerative medicine companies discuss late stage and
commercial products -

PR Newswire

WASHINGTON, April 9, 2013

WASHINGTON, April 9, 2013 /PRNewswire/ -- At the first annual Regen Med
Investor Day, Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), Cytomedix,
Inc. (OTCQX: CMXI) and Mesoblast Limited will be just three of the 16 leading
regenerative medicine companies providing updates on recent corporate and
clinical milestones. The Alliance for Regenerative Medicine also announced
today that the final panelists have been determined for the three disease
sessions which will focus on cardiovascular disease, wound healing and tissue
engineering and CNS diseases. The Regen Med Investor Day is the first investor
event organized specifically for the regenerative medicine sector and will
take place next Wednesday, April 17 at the Harmonie Club, 4 East 60^th Street,
New York, NY.

(Logo: http://photos.prnewswire.com/prnh/20130409/NE91351LOGO)

Presentation Highlights
In addition to the three companies featured below, the program will include
presentations by: Aastrom, Asterias, Athersys, Cytori, Juventas, MiMedx,
NeoStem, Organogenesis, Organovo, Pluristem, Sangamo, StemCells, Inc. and
Tigenix.

ACT is currently conducting three human embryonic stem cell-based clinical
trials for forms of macular degeneration: two in the U.S. and one in Europe.
The company recently announced initiation of treatment of the third patient
cohort in the two U.S. trials.

Cytomedix recently announced the achievement of several key milestones in
their commercialization efforts for autologous regenerative technologies: (i)
on March 8, 2013, the Centers for Medicare & Medicaid Services (CMS) issued
coding and reimbursement claim instructions for autologous PRP in non-healing
chronic wounds; (ii) on March 1, 2013, CMS granted formal approval of the
protocols for AutoloGel under Coverage with Evidence Development (CED); (iii)
in December 2012, a European CE Mark was granted for the Angel cPRP System for
processing blood and bone marrow aspirate; (iv) the FDA granted clearance for
the Angel cPRP System to process bone marrow aspirate; and (v) a Phase 2
clinical study with ALD-301 (Bright Cells) was announced for patients with an
intermittent claudication indication associated with peripheral artery
disease, in collaboration with the NIH. These approvals have the potential to
significantly expand the commercial opportunities for Cytomedix.

Mesoblast Limited recently strengthened its financial position to drive its
independent clinical programs to commercial outcomes, particularly in the
areas of degenerative disease of the lumbar spine and in the treatment of
inflammatory and immune-mediated conditions. In the largest capital raising
for a biotech company this year, the adult stem cell company made a targeted
private placement of shares raising A$170 million and boosting its cash
reserves to A$332 million.

Disease-Focused Sessions
Speakers for the program's three panel discussions have been finalized:

Clinical Outlooks in Cardiovascular Disease

Jason Kolbert, Managing Director, Biotechnology Research, Maxim Group
(moderator)
Ronnda Bartel, Ph.D., CSO, Aastrom Biosciences
Christopher Calhoun, CEO, Cytori Therapeutics, Inc.
Silviu Itescu, M.B.B.S., CEO & President, Mesoblast Limited
Linda Marban, Ph.D., Founder & CEO, Capricor
Leslie Miller, M.D., Director, USF Heart Institute; Director, Cardiovascular
Regenerative Medicine Program, University of South Florida

Regenerative Medicine in Wound Healing & Tissue Engineering

Ted Tenthoff, Managing Director & Senior Biotechnology Analyst, Piper Jaffray
(moderator)
Milka Bedikian, Vice President, Global Marketing, Bioactive Wound Healing,
Organogenesis Inc.
Pierre Gosselin, Ph.D., Senior Director, Business Development, Shire
Regenerative Medicine
Will Li, M.D., President & Medical Director, The Angiogenesis Foundation
Martin Rosendale, CEO, Cytomedix, Inc.
Thomas Serena, M.D., F.A.C.S., CEO & Medical Director, SerenaGroup

Therapeutics for a Broad Range of CNS Diseases

Ren Benjamin, Ph.D., Managing Director & Senior Biotechnology Analyst, Burrill
Securities (moderator)
Aileen Anderson, Ph.D., Associate Professor, Department of Anatomy &
Neurobiology, University of California, Irvine
Lucian Del Priore, M.D., Ph.D., Pierre G. Jenkins Professor, Chairman,
Department of Ophthalmology & Director, Storm Eye Institute
Stephen Huhn, M.D., F.A.C.S., Vice President, Head of the CNS Program,
StemCells Inc.
Gary Rabin, Chairman & CEO, Advanced Cell Technology
Sean Savitz, M.D., Professor of Neurology, University of Texas Medical School,
UTHealth
Gil Van Bokkelen, Ph.D., Chairman & CEO, Athersys, Inc.
Lawrence Wechsler, M.D., Professor & Chair, Department of Neurology,
University of Pittsburgh

About the Regen Med Investor Day
Co-hosted by leading financial firms Burrill & Company, Maxim Group and Piper
Jaffray, this one-day, high-impact program will provide institutional
investors and life science analysts with insight from the industry's leading
small- and mid-cap companies as well as exclusive access to regenerative
medicine's top stakeholders. Full details on the program can be found at
http://alliancerm.org/event/regen-med-investor-day.

RSVP is required. Credentialed investors, life science strategic partners and
members of the media should contact Laura Parsons at lparsons@alliancerm.org
if interested in attending.

About the Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based
non-profit organization that promotes legislative, regulatory, reimbursement,
and financing initiatives necessary to facilitate access to life-giving
advances in regenerative medicine. ARM also works to increase public
understanding of the field and its potential to transform human healthcare,
and provides services to support the growth of its member companies and
organizations. Prior to the formation of ARM, there was no advocacy
organization operating in Washington, DC to specifically represent the
interests of regenerative medicine companies, research institutions,
investors, and patient groups supporting more rapid adoption of technologies
in our field. To learn more about ARM or to become a member, visit
www.alliancerm.org.

Media Contact:
Michelle Linn
Linnden Communications
Phone: 508-362-3087

SOURCE Alliance for Regenerative Medicine

Website: http://www.alliancerm.org
 
Press spacebar to pause and continue. Press esc to stop.